good news! my country's self-developed new drug approved for marketing-Health & Beauty-Hmeonline: Leading B2B Source & Platform Since 2005

good news! my country's self-developed new drug approved for marketing

2022-01-27

On January 25, the official website of the State Food and Drug Administration announced that my country's self-developed new drug omitevirumab injection was approved for marketing.

According to the news, recently, the State Drug Administration approved the listing of omitevirumab injection (English name: Ormutivimab Injection) declared by North China Pharmaceutical Group New Drug Research and Development Co., Ltd. through the priority review and approval process. The developed recombinant human anti-rabies virus monoclonal antibody injection is used for passive immunization of adult rabies virus exposed persons.

Olmotevirumab injection contains high titer anti-rabies virus monoclonal antibody NM57 (IgG1 subtype), which can specifically neutralize the linear neutralizing antigenic epitope in the conservative antigenic site I of rabies virus glycoprotein, thereby preventing Rabies virus infects tissue cells and plays a role in preventing rabies. The listing of this breed provides a new option for passive immunization of rabies virus exposed persons.

DISCLAIMER: All information provided by HMEonline is for reference only. None of these views represents the position of HMEonline, and HMEonline makes no guarantee or commitment to it. If you find any works that infringe your intellectual property rights in the article, please contact us and we will modify or delete them in time.